Ion Channels

SB Drug Discovery Ltd

13th International Conference on Metabolomics and Systems Biology

18 May 2018 | By Conference Series LLC

Euro Metabolomics 2018 will be a platform to investigate on recent research and advancements that can be useful to the researchers.

Nicotinic receptor research paves way for targeted dementia therapy

28 March 2018 | By Dr Zara Kassam (Drug Target Review)

A new study which identifies how acetylcholine impacts learning and memory by acting at different receptors could prove significant in the drive to develop more targeted and effective therapies for dementia...

Assessing neurological ion channel therapeutic and liability targets

10 March 2017 | By Charles River

This webinar explores neurological ion channel therapeutic and liability targets, featuring four subtypes of NMDA receptors. We also discuss the rationale and options for assessment of therapeutic compounds on panels of CNS ion channels for evaluating their risk for CNS liabilities...

Clinical optimism for antagonists targeting certain ion channels

13 December 2016 | By Anindya Bhattacharya (Janssen Research & Development: LLC)

Adenosine triphosphate (ATP)-gated ion channels serve important neurophysiological functions and have been an attractive class of drug target for a decade...

Ion channels: Small molecules versus biologics – the quest for the ideal Na_v1.7 inhibitor

21 September 2015 | By Martin Perkins (National Research Council of Canada), Marzia Martina (National Research Council of Canada)

Ion channels modulate and control many fundamental physiological processes in various tissues and alterations in their functions give rise to a wide range of pathophysiologies, which makes them important drug targets. Indeed, for decades, drugs modulating ion channel activity have been targeted by the pharmaceutical industry. Historically, however, developing drugs…

Research suggests ion channel blocking drugs could be used in cancer therapy

12 August 2015 | By Author: Katie Sadler, Digital Content Producer, Drug Target Review

Research carried out by University of California San Francisco (UCSF) has revealed ion channel blocking drugs could play a part in cancer therapy. The common class of channel blocking drugs, which are used to treat cardiac, neurological, and psychiatric disorders, could prove to be beneficial in cancer treatment according to…

MorphoSys and G7 Therapeutics to develop antibodies targeting GPCRs

4 August 2015 | By Victoria White

MorphoSys and G7 Therapeutics have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors (GPCRs)...

Antibody Discovery Technologies: the partnership between academia and biopharma in the therapeutic monoclonal antibody success story

3 October 2014 | By Andrew G. Popplewell (UCB Pharma), Daniel Lightwood (UCB Pharma), Gillian M. Burgess (UCB Pharma)

The use of monoclonal antibodies and antibody-based molecules as therapeutics to treat patients suffering with severe disease has become a major success story. Due to the exquisite specificity with which they interact with their antigen and the fact that their large binding surface can intervene at sites and targets not…